Comparative Pharmacology
Head-to-head clinical analysis: RECORLEV versus THYROLAR 2.
Peer-Reviewed Evidence
Head-to-head clinical analysis: RECORLEV versus THYROLAR 2.
RECORLEV vs THYROLAR-2
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
RECORLEV (levoketoconazole) is an orally administered corticosteroid biosynthesis inhibitor that suppresses cortisol production by inhibiting adrenal and gonadal steroidogenic enzymes, particularly CYP17A1 (17α-hydroxylase and 17,20-lyase) and CYP11B1 (11β-hydroxylase). It also weakly inhibits CYP3A4 and other CYP enzymes.
Thyrolar-2 is a combination of levothyroxine (T4) and liothyronine (T3), synthetic thyroid hormones. T4 is converted to the active T3 in peripheral tissues. T3 binds to thyroid hormone receptors in the nucleus, modulating gene transcription and increasing metabolic rate, oxygen consumption, and protein synthesis.
150 mg orally twice daily with a high-fat meal.
1/2 to 1 tablet (30-60 mg liotrix) orally once daily, titrated every 2-4 weeks by 1/2 tablet increments based on clinical response and thyroid function tests.
None Documented
None Documented
18 hours; prolonged in renal impairment (up to 45 hours in CrCl <30 mL/min)
6-7 days (euthyroid); clinical context: steady-state reached in 4-6 weeks
Renal: 85% as unchanged drug; Fecal: 10% as metabolites
Renal: 40% (as glucuronide and sulfate conjugates); Fecal: 20% (unabsorbed); Biliary: minor (<5%)
Category C
Category C
Thyroid Hormone
Thyroid Hormone